PF-ILD accompanied lung rehabilitation is a dubious disease in the area of infectious respiratory digestive and endocrine disorders, clinical performance is complex and often involves multi-systematic strain. Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
A comprehensive assessment platform can assist in matching a team of nationally and internationally authoritative experts to provide accurate diagnosis and treatment programs. Treatment and management of PF-ILD accompanied lung rehabilitation requires individualized development of treatment programs, typically including multidimensional management of drug therapy, rehabilitation, regular follow-up, etc. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult to treat infectious respiratory digestive endocrine disorders have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of PF-ILD pulmonary rehabilitation. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.